4—[4—（4—（4—甲氧基苯基）—1—哌嗪基]苯基]—2,4—二氢—3H—1, …

4- [4- [4- ( 4 -甲氧基苯基 ) - 1 -哌嗪基 ]苯基 ]- 2 ,4-二氢 - 3H- 1 ,2 ,4-三唑 - 3-酮 ( 1 )是合成三唑类抗真菌药如伊曲康唑、沙柏康唑 ( saperconazole)、Sch-51 0 4 8、Sch- 56592等药物的重要中间体。本文参考文献[1～ 3 ] ,以 4- [4- ( 4 -甲氧基苯基 ) - 1 -哌嗪基 ]苯胺( 2 )为原料 ,经氯甲酰化、肼解、环合制得 1。反应路线如下 :收稿日期 :1999-12 -14作者简介 :贺宝元 ( 1965 ) ,男 ,硕士 ,助理研究员 ,从事新药研究及开发。Tel:0 2 1-65 442 73 1* 69　　文献 [1,3 ]报道以氯甲酸苯酯或氯甲酸间甲苯酯与 2反应得到相应的…     

4-[[1-[(4-氟苯基)甲基]-1H-2-苯并咪唑基]氨基]-1-哌啶甲酸乙酯的合成

以邻苯二胺为起始原料，经过缩合、氯代、烷基化和取代反应来合成4-[[1-[（4-氟苯基）甲基]-1H-2-苯并咪唑基]氨基]-1-哌啶甲酸乙酯。该合成方法操作简单，总收率达到30．7％。     

2-[4-[(4-氯苯基)苯甲基]-1-哌嗪基]乙醇的合成

目的制备2-[4-[(4-氯苯基)苯甲基]-1-哌嗪基]乙醇。方法以氯苯和苯甲酰氯为起始原料,经付克反应、还原、氯化,再分别与哌嗪、氯乙醇、氯乙酸钠缩合,得到最终产物。结果合成目标产物的总收率为49.1%,中间体4-氯双苯酮,4-氯双苯甲醇,4-氯双苯氯甲烷,1-[(4-氯苯基)苯甲基]哌嗪为鲁南贝特制药有限公司生产确证。结论通过对合成路线的优化,使生产收率提高,降低成本,工艺更适于工业化的生产。     

1，4-二氢-2,6-二甲基-4-（3-硝基苯基）-3,5-吡啶-1羧酸单甲酯的制备

1，4-二氢-2,6-二甲基-4-（3-硝基苯基）-3,5-吡啶二羧酸单甲酯（1）是二氢吡啶类降压药的重要中间体。主要合成方法如下：（1）1,4．二氢-2,6-二甲基-4-（3-硝基苯基）-3，5-吡啶二羧酸甲基氰乙基酯经碱性水解制得，收率60％，但原料不易得；（2）1-乙氧甲基-1，4-二氢-2,6-二甲基-4-（3-硝基苯基）-3，5-吡啶羧酸二甲酯在金属钠和二甲胺基异丙醇存在下水解、酸化制得，收率47．4％，操作繁琐，后处理困难；     

阿立哌唑的合成

4-（2，3-二氯苯基）-1-哌嗪盐酸盐与1，4-二溴丁烷缩合得到1-（4-溴丁基）-4-（2，3-二氯苯基）哌嗪，再与3-氯-N-（3-羟基苯基）丙酰胺反应得3-氯-N-[3-[4-[4-（2，3-二氯苯基）]-1-哌嗪基]丁氧基]苯丙酰胺，最后经闭环制得阿立哌唑，总收率25％。     

4-(4-苯基哌嗪-1-基)-3-O-甲基-D-肌醇的制备及镇咳活性

右旋肌醇甲醚经缩酮制化得3-O-甲基-1，2：5，6-二-O-异亚丙基-D-肌醇，经甲磺酰化、水解、与4-苯基哌嗪缩合制得左羟丙哌嗪类似物4-（4-苯基哌嗪-1-基）-3-O-甲基-D-肌醇，总收率38％。镇咳药效实验表明，目标物对致咳小鼠的镇咳作用明显，但不及左羟丙哌嗪。     

西他列汀合成路线图解

西他列汀（sitagliptin,1）,化学名为（2R）-4-氧代-4-[3-三氟甲基-5,6-二氢[1,2,4]三唑[4,3-a]吡嗪-7（8H）-基]-1-（2,4,5-三氟苯基）-丁-2-胺,是美国Merck公司研发的二肽基肽酶-Ⅳ（DPP-Ⅳ）抑制剂,2006年10月,其磷酸盐（商品名Januvia）作为首个DPP-Ⅳ抑制剂被美国FDA批准上市，临床用于治疗2型糖尿病。1有一个手性中心，其构型为R型，合成关键主要为杂环3-三氟甲基．[1，2，4]三唑[4，3．α]哌嗪（9）的制备和手性的引入。     

4-[1-烷基-5-氧代-1H-1,2,4-三唑-4(5H)-基]-苯甲酸的合成

目的制备用于全合成卡泊芬净类环六脂肽抗真菌剂的关键脂肪酸侧链4-[1-烷基5-氧代-1H-1,2,4-三唑4（5H）-基]-苯甲酸（5）。方法以对氨基苯甲酸（1）为起始原料,经氨基苯氧羰酰化、肼解、甲脒环合及N-烃化4步反应制备目标化合物。结果以42．9％～46．2％的总收率成功合成了目标化合物5a～5n,其结构经电喷雾质谱（ESI—MS）和氢谱（^1HNMR）确证;所有目标化合物均为首次报道。结论该合成路线具有操作简便及收率高等优点,适合工业化生产。     

1-[2-(N-甲基)氨基-2-(2,4-二氯苯基)乙基]-1H-1,2,4-三唑化合物的合成

目的：改进1－[2-（N－甲基）氨基－2－（2,4－二氯苯基）乙基]-1H-1,2,4-三唑的合成方法,降低成本,提高收率,方法：以2－氯－1－（2,4－二氯苯基）乙酮为原料,经三唑烷基化与甲胺反应生成酮亚胺后还原（A法）,或与N－甲基甲酰胺进行Leukart反应（B法）,结果：A和B两种方法制得目标化合物的收率分别为57．6％和63．2％。结论：A和B两种方法原料易得,反应简便,降低了成本,提高了收率。     

2-氨基-2-[2-(4-正辛基苯基)乙基]-1,3-丙二醇盐酸盐的合成工艺改进

目的 合成新型免疫抑制剂2-氨基-2-[2-（4-正辛基苯基）乙基]-1，3-丙二醇盐酸盐（FTY-720）。方法 以苯和正辛酰氯为起始原料，经傅克酰基化、还原、酰化、缩合、还原羰基、还原酯基、去乙酰化和成盐反应得到目的化合物FTY-720，总收率为12．0％。结果与结论 目标化合物的结构经^1H-NMR、IR和MS确证，中间体的^1H-NMR谱和mp值与文献值相符。该合成路线成本低廉，操作简单。     

帕尼培南关键中间体的合成

目的: 改进帕尼培南关键中间体(S)-1-[N-(对硝基苄氧羰基)-1-亚胺基乙基]-3-巯基吡咯烷的合成工艺。方法:以对硝基苄醇为起始原料,经酰化、缩合、与3-R-羟基吡咯烷发生N-烃基化反应,再经磺酰化、缩合、水解反应得到目标化合物。结果与结论:以对硝基苄醇为起始原料经6步反应得到目标化合物,结构经IR、1H-NMR、MS谱图数据确证,比旋光度值与文献报道一致。改进后的工艺总收率为37.2%,各步反应操作简便,条件温和,更适合工业化生产。     

4-(3-氯-4-氟苯胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的合成

目的设计合成4-(3-氯-4-氟苯胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉(ZD1839).方法以3-羟基-4-甲氧基苯甲酸甲酯作为起始原料,经7步反应得到目标化合物.结果与结论目标化合物的结构经IR、1H-NMR和MS确证.本合成反应条件温和,原料易得,操作简便,反应步骤比文献方法(9步)减少两步,反应总收率为34.81%.     

Synthetic analgesics: N-(1-[2-arylethyl]-4-substituted 4-piperidinyl) N-arylalkanamides.

The synthesis of several 4-arylamino-4-piperdinecarboxylic acids is reported. These acids were starting materials for the preparation of alpha-amino esthers, ethers and ketones. Different synthetic approaches are described. Suitable substitution on both nitrogen atoms afforded extremely potent analgesics. Thus, methyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylate (22),N-(4-(methoxymethyl)-2-[2-(2-thienyl)ethyl]-4-piperidinyl)-N-phenylpropranamide (67) and N-[4-acetyl-1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide (82) were found to be respectively 7682, 3987 and 4921 times as potent as morfine. Both cis- and trans-3-methyl homologs of 22 have been prepared. As expected, analgesic activity resides mainly in the cis-isomer.     

Suppression of myocardial protein degradation by the protease inhibitor bis[ethyl(2R,3R)-3-[(S)-methyl-1-[4-(2,3,4-tri-methoxy-phenyl-methyl) piperazine-1-ylcarbonyl]butyl-carbonyl]oxiran-2-carboxylat e]sulfate under hypoxia

The synthetic protease inhibitor bis[ethyl(2R,3R)-3-[(S)-methyl-1-[4-(2,3,4-tri-methoxyphenyl-methyl) piperazine-1-ylcarbonyl]butyl-carbonyl]oxiran-2-carboxylate] sulfate (NCO-700) suppressed both activities of calcium-activated neutral protease and cathepsin B isolated from cardiac muscle, showing 50% inhibition at 46 and 0.8 mumol/l, respectively. A kinetics study using 14C-labelled NCO-700 suggested its incorporation into cultured myocardial cells, demonstrating the half-maximal saturation time at 17 min. Under both aerobic and hypoxic conditions, the reagent inhibited the peptide release from cultured myocardial cells dose-dependently. The amino acid release from heart slices of adult rabbit was also blocked by the drug under hypoxic and glucose-depleted condition. These data and the myocardial infarction size reducing action of NCO-700 might support the view that NCO-700 sensitive protease(s) - possibly, calcium-activated neutral protease and/or cathepsin B - is (are) working to induce an irreversible proteolysis in the process of myocardial cell degradation.     

1-[8-甲氧基-4-[(2-甲基苯基)氨基]-3-喹啉基]-1-丁酮的合成

从商品原料丁酰乙酸乙酯经缩合和胺化直接得 2 -丁酰基 - 3- [(2 -甲氧基苯 )氨基 ]丙烯酸乙酯 ,再经分子内环化、氯化芳构化和胺化 ,得到 1- [8-甲氧基 - 4 - [(2 -甲基苯基 )氨基 ]- 3-喹啉基 ]- 1-丁酮 (SK& F 96 0 6 7)。总收率2 9.7%。     

Preparation and biodistribution of 1-[2-(3-[125I]iodo-4-aminophenyl)ethyl]-4-[3-(trifluoromethyl) phenyl]piperazine and 1-[2-(3-[125I]iodo-4-azidophenyl)ethyl]-4-[3-(trifluoromethyl)phenyl] piperazine

The iodinated analogue of 1-[2-(4-aminophenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]piperazine (PAPP), IPAPP (4), and the corresponding azido compound azido-IPAPP (5) were synthesized. The corresponding no-carrier-added 125I (T1/2 = 60 days, 35-60 keV) labeled compounds were also prepared. High specific binding was observed from in vitro binding studies using rat brain tissue preparation; Ki = 20 and 17.5 nM against [3H]-5-HT. In vivo biodistribution studies in rats showed that azido-[125I]IPAPP passed through intact blood-brain barrier and localized in the brain. Ex vivo autoradiography of rat brain sections exhibited a diffuse uptake pattern, which may be due to specific and nonspecific binding. The results indicate that IPAPP and azido-IPAPP may not be suitable to image the serotonin receptor in the brain.     

Synthesis and pharmacological investigation of novel 1-substituted-4-(4-substituted phenyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as a new class of H1-antihistamine agents

A series of novel 1-substituted-4-(4-substituted phenyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones was synthesized by the cyclization of 2-hydrazino-3-(4-substituted phenyl)-3H-quinazolin-4-one with various one-carbon donors. The starting material, 2-hydrazino-3-(4-substituted phenyl)-3H-quinazolin-4-one, was synthesized from 4-substituted aniline by a novel innovative route. When tested for in-vivo H1-antihistamine activity on conscious guinea-pigs, all the test compounds significantly protected the animals against histamine-induced bronchospasm. The compound 1-methyl-4-(4-chloro phenyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one (VII) was more potent (72.71% protection), and 1-methyl-4-(4-methoxy phenyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one (II) was equipotent (71% protection), when compared with the reference standard, chlorpheniramine maleate (71% protection). Compounds II and VII showed negligible sedation (5% and 8% respectively) when compared with chlorpheniramine maleate (25%). Compounds II and VII could serve as prototype molecules for further development as a new class of H1-antihistamines.     

4-[4-(吡啶-3-基)咪唑-1-基]丁胺的合成

以3-乙酰基吡啶为起始原料,经肟化、磺酰化、氧化、环合、还原得到3-(咪唑-4-基)吡啶,再经与N-(4-溴丁基)邻苯二甲酰亚胺缩合及肼解等反应制得抗菌剂泰利霉素的特定侧链化合物4-[4-(吡啶-3-基)咪唑-1-基]丁胺,总收率24%.     

Synthesis and preliminary evaluation of anticonvulsant activity of some [4-(benzyloxy) benzoyl]- and [4-(benzyloxy) benzyl] aminoalkanol derivatives

A variety of appropriate [4-(benzyloxy) benzoyl]- and [4-(benzyloxy) benzyl] aminoalkanol derivatives [I-XVII] was synthesized and evaluated for anticonvulsant activity using the maximal electroshock (MES) and subcutaneous pentylenetetrazole (ScMet) tests in mice and rats. Neurotoxicity (TOX) was determined by the rotorod test. The most active compounds in the MES test in mice were the appropriate 4-(benzyloxy) benzyl derivatives of (R,S)- and S-(+)-2-amino-1-butanol [XI, XIII], 3-[4-(benzyloxy) benzyl] amino-3-methyl-1-butanol [XV], and S-(+)-2-[4-(benzyloxy) benzyl] amino-3-methyl-1-butanol [XVI]--all exhibiting 100% anti-MES protection (at 30 mg/kg, mice, i.p.) and non-toxic in the active doses. 4-[4-(Benzyloxy) benzyl] amino-1-butanol [X] exhibited activity in both MES and ScMet (100 mg/kg, mice, i.p., 100% anticonvulsant protection, 0.5 h and 4 h after administration, respectively).